| Date | Title | | | 08/08/17 | Entellus Medical Announces New Employee Inducement Option Grants| PLYMOUTH, Minn., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that the Compensation Committee of the Board of Directors of Entellus granted stock options covering an aggregate of 325,500 shares of Entellus common stock to 42 persons newly employed by Entellus as a result of the Spirox, Inc. acquisition.
The stock options were granted effective as of August 4, 2017... |
| | | 08/03/17 | Entellus Medical Announces Second Quarter 2017 Financial Results| PLYMOUTH, Minn., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis, nasal airway obstruction and persistent Eustachian tube dysfunction, today reported its financial results for the quarter ended June 30, 2017.
Recent Highlights and Accomplishments
Revenue of $22.1 million ... |
| | | 07/26/17 | Entellus Medical to Present at the Canaccord Genuity Annual Growth Conference| PLYMOUTH, Minn., July 26, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the less invasive treatment of chronic and recurrent sinusitis, nasal airway obstruction, and persistent Eustachian tube dysfunction, today announced the Company plans to participate in the 37th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA.
Entellus Medical’s ... |
| | | 07/20/17 | Entellus Medical to Report Second Quarter 2017 Financial Results August 3, 2017| Conference call scheduled for Thursday, August 3, 2017 at 3:30pm CT / 4:30pm ET
PLYMOUTH, Minn., July 20, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for less invasive treatment of patients suffering from chronic and recurrent sinus and nasal airway conditions, today announced that it will release its financial results for the second quarter 2017 after the... |
| | | 07/07/17 | Entellus Medical Announces Definitive Agreement to Acquire Spirox| Acquisition Adds Innovative and Minimally Invasive Treatment For Nasal Airway Obstruction – Significantly Expanding Office and Operating Room Based ENT Opportunities
Announces Preliminary Second Quarter 2017 Revenue Results and Updates 2017 Outlook
Conference Call Today at 8:30am ET
PLYMOUTH, Minn., July 07, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced that it has ente... |
| | | 06/01/17 | Entellus Medical to Present at the William Blair Growth Stock Conference| PLYMOUTH, Minn., June 01, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced the Company plans to participate in the 37th Annual Growth Stock Conference hosted by William Blair in Chicago, IL.
E... |
| | | 05/22/17 | The Centers for Medicare & Medicaid Services (CMS) Establishes Coding and Payment for Eustachian Tube Balloon Dilation| PLYMOUTH, Minn., May 22, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced that the CMS has established a unique billing code and payment for endoscopic balloon dilation to treat Eustachian tube d... |
| | | 05/03/17 | Entellus Medical Announces First Quarter 2017 Financial Results| PLYMOUTH, Minn., May 03, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ: ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter ended March 31, 2017.
Recent Highlights and Accomplishments
Revenue of $19.1 million in the first quarter of 2017, an increase of 13% year-over-... |
| | | 04/20/17 | Entellus Medical to Present at the Deutsche Bank Annual Health Care Conference| PLYMOUTH, Minn., April 20, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced the Company plans to participate in the 42nd Annual Health Care Conference hosted by Deutsche Bank in Boston, MA.
En... |
| | | 04/19/17 | Entellus Medical to Report First Quarter 2017 Financial Results on May 3, 2017| Conference call scheduled for Wednesday, May 3, 2017 at 3:30pm CT / 4:30pm ET
PLYMOUTH, MN, April 19, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, as well as the treatment of patients with Eustachian tube dysfunction, today announced that it will release its financial results ... |
| | | 04/12/17 | Entellus Medical Receives FDA 510(k) Clearance for Eustachian Tube Indication| PLYMOUTH, Minn., April 12, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the Company has received 510(k) clearance from the United States Food and Drug Administration (FDA) for use of its XprESS ENT Dilation System in patients with persistent Eustachian tube dysf... |
| | | 02/21/17 | Entellus Medical Announces Fourth Quarter and Full Year 2016 Financial Results| PLYMOUTH, Minn., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today reported its financial results for the quarter and year ended December 31, 2016.
Recent Highlights and Accomplishments
Revenue of $21.7 million in the fourth quarter of 2016, an increase of 2... |
| | | 02/01/17 | Entellus Medical to Report Fourth Quarter and Full Year 2016 Financial Results on February 21, 2017| Conference call scheduled for Tuesday, February 21, 2017 at 3:30pm CT / 4:30pm ET
PLYMOUTH, Minn., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it will release its financial results for the fourth quarter and full year 2016 after the close of tr... |
| | | 01/25/17 | Entellus Medical Announces Pricing of Public Offering of Common Stock| PLYMOUTH, Minn., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (the “Company” or “Entellus Medical”) (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients, today announced the pricing of its underwritten public offering of 3,530,000 shares of its common stock at a price of $17.00 per share before... |
| | | 01/25/17 | Entellus Medical Announces Proposed Public Offering of Common Stock| PLYMOUTH, Minn., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (the “Company” or “Entellus Medical”) (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients, today announced that it has commenced an underwritten public offering of $60.0 million of shares of its common stock. The offering is expecte... |
| | | 01/05/17 | Entellus Medical Announces Management Promotions and Preliminary Revenue for Fourth Quarter and Full Year 2016| PLYMOUTH, Minn., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the promotion of Thomas Williamson to the position of Vice President of Sales; the resignation of Jim Surek as Vice President of Sales, and the promotion of Jonelle Burnham to the position of... |
| |
|
Print Page | 
E-mail Page | 
RSS Feeds | 
E-mail Alerts | 
Financial Tear Sheet